{"id":"nct:NCT07517263","kind":"trial","title":"An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2026,"published":"2026-04-08","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07517263","source_url":"https://clinicaltrials.gov/study/NCT07517263","archive_url":"https://space-kitty.com/papers/nct:NCT07517263","updated":"2026-10-14","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Cardiovascular Disease and Lipoprotein(a)"],"details":{"acronym":null,"status":"ACTIVE_NOT_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":5700,"sponsor":"Novartis Pharmaceuticals","conditions":["Cardiovascular Disease and Lipoprotein(a)"],"interventions":["DRUG: Pelacarsen (TQJ230)"],"start_date":"2026-05-11","start_date_type":"ACTUAL","primary_completion_date":"2030-01-09","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}